ArticleJournal of geriatric oncology2021
Serological response to COVID-19 vaccination in patients with cancer older than 80 years.
Article in Journal of geriatric oncology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 9 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 9 syntheses or guidelines pooled it.
- Seroconversion rate after COVID-19 vaccination in patients with solid cancer: A systematic review and meta-analysis.Human vaccines & immunotherapeutics · 2022Pooled it
- A systematic review and meta-analysis of immune response against first and second doses of SARS-CoV-2 vaccines in adult patients with hematological malignancies.International immunopharmacology · 2022Pooled it
- Seroconversion following the first, second, and third dose of SARS-CoV-2 vaccines in immunocompromised population: a systematic review and meta-analysis.Virology journal · 2022Pooled it
- Antibody response after vaccination against SARS-CoV-2 in adults with hematological malignancies: a systematic review and meta-analysis.Haematologica · 2022Pooled it
- Immunogenicity of COVID-19 vaccines in patients with hematologic malignancies: a systematic review and meta-analysis.Blood advances · 2022Pooled it
- Efficacy of covid-19 vaccines in immunocompromised patients: systematic review and meta-analysis.BMJ (Clinical research ed.) · 2022Pooled it
- Short-term effectiveness of COVID-19 vaccines in immunocompromised patients: A systematic literature review and meta-analysis.The Journal of infection · 2022Pooled it
- Immunogenicity of COVID-19 mRNA vaccines in immunocompromised patients: a systematic review and meta-analysis.European journal of medical research · 2022Pooled it
- Immunological and clinical efficacy of COVID-19 vaccines in immunocompromised populations: a systematic review.Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases · 2022Pooled it
- Article
- Determinants of COVID-19 Disease Severity-Lessons from Primary and Secondary Immune Disorders including Cancer.International journal of molecular sciences · 2023Review
- Review
- Article
- Willingness to receive COVID-19 vaccination and adverse effects after vaccination in breast cancer survivors during the COVID-19 pandemic: a cross-sectional retrospective study of a Chinese population.Annals of translational medicine · 2023Article
- Global caregiver perspectives on COVID-19 immunization in childhood cancer: A qualitative study.Frontiers in public health · 2023Article
- Prevalence and factors of COVID-19 vaccine refusal among solid cancer patients in China: an application of the health belief model.Frontiers in public health · 2023Article
- Safety of mRNA-COVID-19 Vaccines in Patients With Thoracic Cancers.Clinical lung cancer · 2023Article
- SARS-CoV-2 seroprevalence and infection rate in Manila, Philippines prior to national vaccination program implementation: a repeated cross-sectional analysis.Tropical medicine and health · 2022Article
- Geriatric risk factors for serious COVID-19 outcomes among older adults with cancer: a cohort study from the COVID-19 and Cancer Consortium.The lancet. Healthy longevity · 2022Article
- COVID-19 vaccination in cancer patients: a narrative review.The Journal of international medical research · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Central studies carried out on vaccines against the severe acute respiratory syndrome coronavirus 2 (SARS-COV2) excluded patients receiving immunosuppressive therapy and those diagnosed with an immunosuppressive condition. Moreover, there are no data on vaccine efficacy regarding older patients with cancer.
objectivesThe primary objective was to evaluate the seroprevalence of the SARS-CoV2 IgG in older patients (aged ≥80 years) diagnosed with solid or hematological malignancies, one month after administering the second dose of the BNT162b2 vaccine. MATERIALS AND
methodsWe screened 74 older patients with cancer, 45 of them accepted to receive the vaccination and collected serum samples from 36 patients; a group of medical doctors and nurses from our hospital was used as a control in a 1:2 ratio.
resultsThe median age was 82 years (range 80-89). Median serum IgG were 2396,10 AU/ml (range 0-32,763,00) in patients with cancer and 8737,49 AU/ml (398.90-976,280,00) in the control group, p < 0.0001. Additional subgroup analyses were performed comparing males and females, patients treated with chemotherapy versus other therapies (immunotherapy, targeted therapy), solid tumors versus hematological malignancies, early (I-II) versus advanced (III-IV) stage of disease, continuative corticosteroid use or not. None of them reached statistical significance.
conclusionOur study shows for the first time that patients with cancer aged ≥80 years can have a serological response to the BNT162b2 COVID-19 vaccine one month after vaccination and consequently support the vaccination campaign currently underway in this frail population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.